Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
44.95
-2.15 (-4.56%)
At close: Mar 9, 2026
-42.37%
Market Cap 3.99B
Revenue (ttm) 7.46M
Net Income (ttm) -243.50M
Shares Out 88.66M
EPS (ttm) -2.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 308,917
Average Volume 587,595
Open 44.00
Previous Close 47.10
Day's Range 44.00 - 46.90
52-Week Range 39.75 - 79.90
Beta 0.45
RSI 43.89
Earnings Date Feb 26, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 35
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6657
Full Company Profile

Financial Performance

In 2024, TPE:6657's revenue was 7.75 million, an increase of 8.26% compared to the previous year's 7.16 million. Losses were -231.08 million, -11.25% less than in 2023.

Financial Statements

News

There is no news available yet.